Third Development Candidate News Today

-Contineum is focused on leading the Neuroscience, Inflammation and Immunology field- -Successful completion of Initial Public Offering with strong syndicate of existing and new investors- ...

Preliminary Dose Escalation Data on ROS1-selective Inhibitor NVL-520 to be Presented in the "New Drugs on the Horizon" Oral Plenary Session New Preclinical...